Spotlight

Mar 01, 2024

Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals

https://www.oneamyloidosisvoice.com/wp-content/uploads/2024/03/Full-Article-hATTR-Holistic-Care-Con…

Jul 11, 2023

Amyloidosis now a hot topic in cardiac imaging due to new drug treatment

July 11, 2023 | Cardiovascular Business For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in…

A vision toward a more holistic approach to care in hereditary ATTR amyloidosis

The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases

Health System First in Nation to Offer Treatment for Hereditary Amyloidosis

Stem Cell Transplantation Produces Prolonged Survival With Improved Safety in Patients With AL Amyloidosis

Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

Gene Editing Offers Hope for Progressive Cardiomyopathy Due to Amyloidosis

Veterans and AL Amyloidosis

The Coverage Battle Continues for Veterans With Transthyretin Amyloidosis

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.